Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Wegovy, Rybelsus, or a compounded formulation. The long answer along with a dosage chart you can find below. We did all the research for you, finding out how semaglutide dosing works and the best ...

Semaglutide 2.4 mg is marketed under the brand name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...

Get Wall Street's Hottest Chart ... and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. Also Read: Popular Ozempic, Wegovy ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

Novo Nordisk announced that a higher dose of semaglutide (Wegovy) generated higher placebo-adjusted weight loss at 72 weeks among adherent patients than the lower, approved dose (18.3% vs.